Drugs / EffCaMgCit
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03565913 | Jan 2017 → Dec 2026 expected | end stage renal failure | University of Texas Southwestern Medical Center | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05998863 | Apr 2024 → Jun 2026 | magnesium deficiency, osteoporosis | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03812380 | Jan 2019 → Aug 2021 | magnesium deficiency, osteoporosis | University of Texas Southwestern Medical Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EffCaMgCit | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05998863 ↗ |
| Route | Oral | “to be dissolved/suspended before swallowing” NCT05998863 ↗ |